NO20032840L - Heterocykloindazol- og azaindazol-forbindelser som 5- hydroksytryptamin-6-ligander - Google Patents

Heterocykloindazol- og azaindazol-forbindelser som 5- hydroksytryptamin-6-ligander Download PDF

Info

Publication number
NO20032840L
NO20032840L NO20032840A NO20032840A NO20032840L NO 20032840 L NO20032840 L NO 20032840L NO 20032840 A NO20032840 A NO 20032840A NO 20032840 A NO20032840 A NO 20032840A NO 20032840 L NO20032840 L NO 20032840L
Authority
NO
Norway
Prior art keywords
optionally substituted
aryl
alkyl
heterocycloindazole
hydroxytryptamine
Prior art date
Application number
NO20032840A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032840D0 (no
Inventor
Ping Zhou
Derek Cecil Cole
Michael Gerard Kelly
William Joseph Lennox
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20032840D0 publication Critical patent/NO20032840D0/no
Publication of NO20032840L publication Critical patent/NO20032840L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20032840A 2000-12-22 2003-06-20 Heterocykloindazol- og azaindazol-forbindelser som 5- hydroksytryptamin-6-ligander NO20032840L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25762700P 2000-12-22 2000-12-22
PCT/US2001/047935 WO2002051837A2 (en) 2000-12-22 2001-12-11 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands

Publications (2)

Publication Number Publication Date
NO20032840D0 NO20032840D0 (no) 2003-06-20
NO20032840L true NO20032840L (no) 2003-08-20

Family

ID=22977057

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032840A NO20032840L (no) 2000-12-22 2003-06-20 Heterocykloindazol- og azaindazol-forbindelser som 5- hydroksytryptamin-6-ligander

Country Status (20)

Country Link
US (3) US6767912B2 (es)
EP (1) EP1355904B1 (es)
JP (1) JP4307073B2 (es)
KR (1) KR20030062442A (es)
CN (1) CN1281605C (es)
AR (1) AR034283A1 (es)
AT (1) ATE368658T1 (es)
BR (1) BR0116323A (es)
CA (1) CA2432654A1 (es)
DE (1) DE60129746T2 (es)
DK (1) DK1355904T3 (es)
EA (1) EA200300717A1 (es)
ES (1) ES2290187T3 (es)
HU (1) HUP0400684A2 (es)
IL (1) IL156517A0 (es)
MX (1) MXPA03005432A (es)
NO (1) NO20032840L (es)
PL (1) PL363241A1 (es)
WO (1) WO2002051837A2 (es)
ZA (1) ZA200305622B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005432A (es) * 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6.
WO2002085853A2 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2444095A1 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1401813B1 (en) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
DE60322186D1 (de) * 2002-02-12 2008-08-28 Organon Nv 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
ES2201899B1 (es) 2002-04-01 2005-06-01 Almirall Prodesfarma, S.A. Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
MXPA06000700A (es) * 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
ES2222828B1 (es) * 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
HRP20090419T1 (hr) 2004-01-02 2009-09-30 Suven Life Sciences Limited Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
CA2557268A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
KR100843526B1 (ko) 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
AU2005219517A1 (en) 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
ATE460415T1 (de) * 2004-11-29 2010-03-15 Warner Lambert Co Therapeutische pyrazoloä3,4-büpyridine und - indazole
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
BRPI0614341A2 (pt) * 2005-08-15 2011-03-29 Wyeth Corp composto; método para o tratamento de um distúrbio do sistema nervoso central relacionado com o receptor de 5-ht6 ou afetado por ele em um paciente que deste necessite; composição farmacêutica; e processo
CA2620105A1 (en) 2005-08-25 2007-03-01 F. Hoffman-La Roche Ag P38 map kinase inhibitors and methods for using the same
WO2007032572A1 (en) * 2005-09-15 2007-03-22 Korea Reserach Institute Of Chemical Technology N-substituted-1h-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006306497A1 (en) * 2005-10-24 2007-05-03 Janssen Pharmaceutica, N.V. 3-piperidin-4-yl-indole ORL-1 receptor modulators
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
AU2007235499A1 (en) * 2006-04-05 2007-10-18 Wyeth Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
US20080200471A1 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6' substituted compounds having 5-ht6 receptor affinity
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2008124848A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101730680A (zh) * 2007-05-24 2010-06-09 记忆医药公司 具有5-ht6受体亲和力的4’取代的化合物
AU2008286760A1 (en) * 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
JP5529743B2 (ja) 2007-11-05 2014-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 選択的11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤としての7−アザインドール誘導体
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ,エルエルシー. 5−リポキシゲナーゼ活性化タンパク質阻害剤
US8546576B2 (en) 2008-06-06 2013-10-01 Sk Biopharmaceuticals Co., Ltd. 3 or 4-substituted piperidine compounds
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Fxr有限責任公司 含有雙環核心部分之新穎lxr調節劑
CN109678776B (zh) * 2019-01-24 2020-07-14 苏州大学 3-芳基琥珀酰亚胺类化合物的制备方法
EP4216949A4 (en) * 2020-09-28 2024-12-11 Yale University Selective agonists of 5-ht2a receptor and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670447A (en) * 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US5196425A (en) * 1988-09-02 1993-03-23 Janssen Pharmaceutica N.V. Antihypertensive 3-piperidinyl-indazole derivatives
US5409941A (en) 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
WO1997049698A1 (en) * 1996-06-21 1997-12-31 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
EP0944595B1 (en) * 1996-11-26 2003-10-01 NPS Allelix Corp. 5-cyclo indole compounds as 5-ht1d receptor ligands
ZA98376B (en) 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6133287A (en) 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
US6066637A (en) 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
ATE375990T1 (de) * 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
US6191141B1 (en) 1999-08-12 2001-02-20 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
MXPA03005432A (es) * 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6.

Also Published As

Publication number Publication date
US6903112B2 (en) 2005-06-07
DE60129746T2 (de) 2008-04-30
CN1553910A (zh) 2004-12-08
JP4307073B2 (ja) 2009-08-05
ES2290187T3 (es) 2008-02-16
WO2002051837A3 (en) 2003-01-16
NO20032840D0 (no) 2003-06-20
ATE368658T1 (de) 2007-08-15
HUP0400684A2 (hu) 2004-07-28
DE60129746D1 (de) 2007-09-13
US20040092526A1 (en) 2004-05-13
DK1355904T3 (da) 2007-10-15
PL363241A1 (en) 2004-11-15
AR034283A1 (es) 2004-02-18
ZA200305622B (en) 2004-10-21
EA200300717A1 (ru) 2003-12-25
BR0116323A (pt) 2003-10-14
WO2002051837A2 (en) 2002-07-04
US6767912B2 (en) 2004-07-27
CA2432654A1 (en) 2002-07-04
US20050124603A1 (en) 2005-06-09
EP1355904A2 (en) 2003-10-29
US20020198213A1 (en) 2002-12-26
EP1355904B1 (en) 2007-08-01
JP2004518668A (ja) 2004-06-24
MXPA03005432A (es) 2003-09-10
CN1281605C (zh) 2006-10-25
KR20030062442A (ko) 2003-07-25
IL156517A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
NO20032840L (no) Heterocykloindazol- og azaindazol-forbindelser som 5- hydroksytryptamin-6-ligander
EP2206709A3 (en) Thiophene derivatives as antiviral agents for flavivirus infection
ATE322264T1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
WO2002081448A1 (en) Benzamidine derivative
BR0300018A (pt) Compostos oxo ou oxi-piridina como moduladores do receptor 5-ht4
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
DE60226764D1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
EP1593667A4 (en) Amine derivative
CO5601027A2 (es) Derivados de imidazol-4-il-etinil-piridina
CA2383583A1 (en) Benzopyran derivative
ATE503746T1 (de) Neue imidazolidinderivate
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
NO20054787D0 (no) Indenderivater som farmasotiske midler
DK1175410T3 (da) Pesticide triazinderivater
WO2001077090A3 (en) Isothiazole derivatives and their use as microbicides
WO2002079753A3 (en) 2-aminobenzoxazole derivatives and combinatorial libraries thereof
WO2000040242A3 (de) Herstellung eines mittels gegen hepatitis b-, hi-, paramyxo- und orthomyxo-viren
DE60043497D1 (de) 4-Substituierte-3,6-Anhydro-Galaktosederivate und ihre pharmazeutische Verwendung
AU2002351125A1 (en) Microbiocidal n-phenyl-n-(4-(4-pyridyl)-2-pyrimidin-2-yl)-amine derivatives
WO2004108687A3 (en) Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
EP1803719A4 (en) 1,5-DIHETEROCYCLUS-1H-triazole
WO2005080368A3 (en) Benzopyran compound useful for the treatment of arrhytmia
DE60105801D1 (de) Naphtholderivate
EA200301079A1 (ru) Терапевтическое средство по поводу повышенной чувствительности мочевого пузыря

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application